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2 CHAPTER 1  INTRODUCTION 
1.1  Decision  IX/19  of the  Parties  to  the  Montreal  Protocol  reqmres  Parties 
requesting essential use nominations for chlorofluorocarbons CFCs for metered-dose 
inhalers  (MDis) to  present to  the  Ozone  Secretariat an  initial  national  or regional 
transition strategy if possible by 31  January  1998, and  in  any  case  by  31  January 
1999.  The  European  Community  is  a  Party  to  the  Montreal  Proklc.'t>l,  and  this 
document is its transition strategy prepared in accordance with decision IX/19 of the 
Parties. The European Community believes that a transition strategy is  necessary to 
set out how the transition out of CFCs in MD  Is is to be managed such that the CFCs 
can  be  phased  out as  quickly  as  possible  without putting  in jeopardy  supplies  of 
necessary medicines to patients in need. 
1.2  The European Community, on behalf of the Member States, submits a joint 
request every year to the Parties for the continued use of CFCs to.manufacture MDis. 
Under Regulation (EC)  3093/94 on Substances that Deplete the  Ozone  Layer,  the 
European Commission, with the assistance of a Management Committee of Member 
States, determines every year: 
•  the essential uses which shall be permitted in the Community 
•  the users who may take advantage of  these essential uses 
•  the quantities of  CFCs which may be used for essential uses 
Given that the supply of  CFCs for MDis is managed on a Community-wide basis, the 
transition away from the use of CFCs should also be managed on a Community-wide 
basis. As far as possible, the approval and introduction of CFC-free products and the 
withdrawal of CFCs from the manufacture of MD  Is should be coordinated across the 
'  Community. This will prevent any part of the Community remaining dependent on 
obsolete CFC-containing medicines long after the rest of the Community has moved 
over to the new CFC-free products. 
1.3  This transition strategy draft has been prepared by the European Commission 
with the  assistance of an ad  hoc  working  group comprising  representatives of the 
Community's  pharmaceutical  and  ozone  management  committees,  Member  State 
Health  Authorities,  the  European  Federation  of  Pharmaceutical  Industries' 
Associations (EFPIA), the International Pharmaceutical Aerosols Consortium (!PAC), 
the  Standing Committee of European Doctors, the European Federation of Asthma 
and Allergy Associations (EFA), the European Chemical Industry Council (CEFIC) 
and  other  experts  in  the  field.  Detailed  comments  have  also  been  received  and 
incorporated  from  many  organisations  including  representatives  of  Nurses, 
Pharmacists, Asthma Patients, Doctors, and the manufacturers of asthma medicines 
The European Commission is most grateful for the invaluable help and co-operation 
of  these individuals and organisations in preparing this strategy. 
3 CHAPTER2  EXECUTIVE SUMMARY 
2.1  This  document  is  the  European  Community's  transition  strategy  for  the 
phaseout of  CFCs in metered-dose inhalers (MD Is). It is to be submitted to the Parties 
to  the  Montreal  Protocol  in accordance  with  Decision  IX/19.  The  purpose  of the 
strategy  is  to  describe  how  the  phaseout  of  CFC-containing  MDts  and  their 
replacement by CFC-free MDis is to be managed in the Community. 
2.2  The  phaseout of CFCs  in  MDis  is  necessary  because,  under  the  Montreal 
Protocol on substances that deplete the ozone layer, the production and consumption 
of CFCs is  now banned in the European Community and throughout the  developed 
world.  Developing countries  have  a  grace  period  under  which  the  production  and 
consumption of CFCs may continue to meet their basic domestic needs.  Developing 
countries will phase out these substances in 2010. 
2.3  CFCs  are  still  currently  available  in  Europe  for  the  manufacture  of MDis 
through the essential uses exemption. This permits the continued production and  use 
of CFCs  for  agreed  essential . uses  where  technical  and  economically  feasible 
alternatives  are  not  available.  The  treatment  of asthma  and  chronic  obstructive 
pulmonary  disease  (COPD)  by  metered-dose  inhalers  containing  CFCs  has  been 
acknowledged  as  an  essential  use  by  the  Parties  to  the  Montreal  Protocol.  Some 
10,000  tonnes  per year  of CFCs  are  used  worldwide  to  manufacture  around  500 
million MDis. 
2.4  Alternatives to CFC-containing MDis are now becoming available throughout 
the European Community.  Suitable alternatives include  dry  powder inhalers (DPis) 
and MD  Is with HFC instead of CFC propellant. Under the rules of the essential uses 
exemption,  CFCs  will  no  longer  be  authorised  for  products  where  acceptable 
alternatives are available. In some parts of the  European Community, a majority of 
patients  are  already  treated  with  DPis  rather  than  MDis.  Throughout  the  entire 
Community, CFC-free MDis are  now being introduced such that,  by  the year 2003, 
there should be no further need for CFC-containing MDis in the Community. 
2.5  Before  CFC-free  MDis can be  prescribed  to  patients,  they  need  to  receive 
marketing  authorisation from the  competent authorities.  Such authorisation  is  only 
granted when the competent authority is satisfied that the proposed alternative product 
is safe and effective. Obtaining marketing authorisation for CFC-free MDis across the 
entire  European Community is  currently a  lengthy  process,  because  each  Member 
State conducts its own review and authorisation procedures. This strategy proposed a 
means  whereby  Member  States,  the  Commission  and  the  manufacturers  can  co-
operate to streamline the approvals procedure. An efficient, streamlined procedure for 
approving CFC-free products across the  Community is  an important and  necessary 
part of the  strategy  to  phaseout  CFCs  in  MDis:  Competent  authorities  should  no 
longer give marketing authorisation for new CFC-containing inhalers. 
2.6  While the  early phaseout of CFCs  is  important,  so  too  is  the  health of the 
millions of patients, including children and the elderly, who currently depend on their 
4 CFC inhaler. CFCs should only be withdrawn once these patients have  access  to  a 
satisfactory  alternative.  This  strategy  confirms  the  commitment  of the  European 
Commission to safeguard supplies of  necessary medicines and the health and safety of 
patients during the transition. This is to be done by ensuring that CFCs will only be 
withdrawn from particular CFC products or categories of product when a sufficient 
nwnber of acceptable alternatives is available.  The nwnber of alternatives required 
before CFCs can be phased out varies from product to product and fron'l category to 
category, depending on the extent and pattern of  use. 
2.7  The strategy  recognises  that  there  are  differences  between  Member  States 
regarding the CFC products prescribed, the balance between DPis and MDis, and the 
nwnber of  products which will require alternatives. Nevertheless, there are important 
similarities for some of the most widely-prescribed products, and it is likely that the 
transition out of CFC-MDis  will  occur quickly across  the  entire  Community  once 
alternatives are  available for  the main types of inhaler.  Where  particular problems 
persist, small quantities of CFCs for specific MDI products may be authorised as part 
of  the annual Commission decision in essential uses in the Community. 
2.8  The European Community  is  a major exporter of CFC-containing MDis to 
both developed and developing countries. These exports will need to continue even 
after the transition has been accomplished in the Community in order to ensure that 
patients, especially in developing countries, are not deprived of essential medicines. 
MDI manufacturers based in the European Community are expected to help promote 
the transition away from CFC-containing MDis in their export markets. They should 
ensure  that,  wherever  possible,  patients  relying  on  MDis produced  in  Europe  are 
given  access  to  CFC-free  inhalers  and  thereby  benefit  from  the  experience  of 
transition in Europe. 
2.9  Patients are at the centre of the transition and need to  be  fully  aware of the 
issues involved. Most if not all patients will successfully switch from a CFC  inhaler 
to a CFC-free inhaler given sufficient information, advice and help. Information needs 
to  be  coordinated  to  ensure  that  doctors,  other health  professionals  arid  patients' 
associations  provide  accurate,  coherent and  useful  information  to  patients  before, 
during  and  after transition.  Wherever possible,  new  patients  should  be  started  on 
CFC-free  inhalers,  and  manufacturers  should  no  longer  develop  and  market  new 
inhalers containing CFCs. 
2.10  The Community's annual essential use nomination for CFCs to UNEP will be 
based on the best available forecasts of  the future availability of alternatives - the so-
called 'targets and timetables' approach. Through its decision on essential uses each 
year,  the  Commission will  ensure  that  CFCs  remain  available  for  those  products 
where they are  still required,  but are  not authorised for products  where  acceptable 
alternatives are available. In this way, and with the co-operation and involvement of 
Member States, MDI manufacturers, patients and health professionals, the phaseout of 
CFCs  in MDis in the  European Community  can take  place  quickly  and  smoothly 
while safeguarding the health and safety of  patients. 
5 CHAPTER  3  CFCs and MDis 
3.1  CFC-containing MDis have  proved to  be  a  low-cost,  effective  and reliable 
means to treat respiratory diseases such as astluna and chronic obstructive pulmonary 
disease  (COPD).  These  medicines  are  important  as  the  incidence  of astluna  in 
developed countri,es is around 5 - 8% of the population and increasing at an average 
rate of around 5% per year. On average throughout the European Coaununity, some 
80% of inhaled medicines are  delivered by  MDis,  with the  rest  delivered by dry 
powder inhalers (DPis) and nebulisers. There are currently some 500 million MDis 
used annually worldwide, resulting in the use and emission of around 1  Q,OOO  tonnes 
CFCs per year.  In general,  CFC 12 is used as a propellant in the MDis, and CFC 11 
or CFC 114 is used to dissolve or suspend the drug being delivered to the patient. 
3.2  CFCs  released  to  the  atmosphere  eventually  find  their  way  up  to  the 
stratosphere where they destroy the  ozone layer which protects the  earth's surface 
from harmful ultra-violet radiation.  During the last few years, the ozone layer has 
been severely depleted, both over the Antarctic region where the "ozone hole" now 
appears annually, but also over the northern hemisphere. Ozone depletion up to 40% 
has been recorded in each of  the last three years over Northern Europe. 
3.3  In order to prevent the destruction of  the earth's ozone layer, the international 
community has agreed a Convention (the Vienna Convention,  1985) and a Protocol 
(the  Montreal  Protocol,  1987).  The  Montreal  Protocol  requires  the  progressive 
phaseout of the production and consumption of substances which destroy the ozone 
layer. It is therefore vital for those industries which use CFCs to find alternatives as 
quickly as possible. 
3.4  Under the Montreal Protocol, the production and consumption of CFCs was 
phased out in developed countries from 1 January 1996. This phaseout occurred one 
year earlier  in the European  Community.  However,  under the Montreal  Protocol, 
temporary  exceptions  to  the  phaseout  can  be  made  under  the  "essential  uses" 
procedure. This procedure provides that a particular use of CFCs may be declared 
"essential" where: 
a)  it is necessary for the health, safety or is crucial for the functioning of  society 
(encompassing cultural and intellectual aspects);  and  -
b)  there  are  no available  technically  and economically feasible  alternatives  or 
substitutes that are acceptable from the standpoint of  environment and health 
Further, the production and consumption of  CFCs for essential uses may be permitted 
only if: 
a)  all economically feasible steps have been taken to minimise the essential use and 
any associated emissions of  the controlled substance; and 
b). the controlled substance is not available in sufficient quantity and quality from 
existing stocks of  banked or recycled controlled substances, also hearing in mind 
the developing countries' need  for controlled substances. 
6 (Decision /V/25 of  the Parties to the Montreal Protocol) 
3.5  The use of CFCs for the manufacture of MDis has qualified for essential use 
status  since the  initial phaseout of CFCs.  This  is  because  the  provision of asthma 
medication is clearly necessary to the health of society, and, at least until recently, no 
technically and  economically feasible alternatives or substitutes to  CFCs have been 
available. The following quantities of  CFCs have been approved by the Parties for the 
manufacture of  MD Is in the European Community: 
Year of  use 
1996 
1997 
1998 
1999 
Tonnes of  CFCs approved by the Parties 
7546 
6635 
5610 
5000 
3.6  Since the phaseout of CFCs was first agreed, the international pharmaceutical 
industry has been researching into alternative substances to use in MDis. The result is 
that some technically and economically feasible alternatives to  CFCs now exist and 
are  becoming  increasingly  available  for  the  successful  treatment of some types of 
asthma and COPD.  The increased availability of clinically effective, technically and 
economically feasible alternatives will mean that, progressively, CFCs will no longer 
meet  the  essential  use  criteria  under  the  Montreal  Protocol  and  will  therefore  no 
longer be authorised for the manufacture of  those types of  MDI for which alternatives 
exist. 
3. 7  All the signatories to the Montreal Protocol, including all  the Member States 
of the  European  Community,  are  committed  to  phasing  out  the  production  and 
consumption  of ozone-depleting  substances  as  quickly  as  possible.  Part  of this 
commitment includes minimising exemptions from  the  Protocol  under the essential 
uses  procedures.  Therefore,  the  European Commission and  Member  States  will  be 
seeking early opportunities to reduce the quantities of CFCs approved for use in the 
manufacture  of MDis  in  the  European  Community.  Equally,  however,  all  those 
involved recognise an equally important obligation to ensure that asthma and COPD 
patients  continue  to  receive  the  medicines  they  require.  Therefore,  the  following 
principles have been agr~e~ to guide the phase out of  CFCs in MD Is: 
Principle 1:  That  all  those  involved  will  promote  the  transition  to  non-CFC 
alternatives 
Principle 2:  That the  health  and  safety  of patients  during  the  transition  will  be 
safeguarded 
Principle 3:  That the nomination, approvals and licensing systems will be operated 
with efficiency, consistency and transparency. 
7 3.8  This draft strategy sets out a policy for the management of  the transition out of 
CFC-containing inhalers based on th~se three principles. In particular, the strategy; 
•  reviews current and future demand for asthma and COPD therapy in the European 
Co nun  unity 
•  summarises current progress in the development of alternatives  to  CFC inhalers, 
including forecasts of  the rate of  introduction of  alternatives 
•  sets out a policy to facilitate the efficient and fast review and approval of non-CFC 
alternatives throughout the European Community as a whole 
•  sets  out  an  approach  to  pharmacovigilance  and  safety  monitoring  of the  new 
products to ensure that patient safety is maintained 
•  sets out a procedure by which CFCs can be progressively phased out as alternative 
medicines and treatments become available 
•  makes  recommendations  to  raise  the  awareness  of doctors  and  patients  and  to 
promote the rapid and successful acceptance of  CFC-free medicines 
•  considers how to treat MDis manufactured in the European Community for export, 
particularly to developing countries 
•  reviews  the  continued  production  and  supply  of CFCs  m  the  EC  during  the 
transition 
3.9  The  European  Community  is  the  world's  largest  manufacturer  of  MDI 
inhalers,  25%  of which  are  exported.  This  means  that  we  have  a  particular 
responsibility  to  develop  and  promote  environmentally  safe  inhalers  while,  at  the 
same time, meeting the  needs of patients throughout the world who  depend on our 
products.  This  strategy  puts  forward  a  means  through  which  both  these 
responsibilities  can  be  met,  and  the  _transition  away  from  CFCs  be  successfully 
managed across all the Member States of  the European Community. 
8 CHAPTER4  PATIENT  NEEDS 
4.1  The prevalence of asthma and chronic obstructive pulmonary disease (COPD) 
is increasing  world-wide.  There are at least 25 million people with asthma in Europe. 
The prevalence of  asthma has risen over the last 20 years, especially amongst children 
where it now approaches 15% in Western Europe. Asthma has enormous health and 
economic costs and is probably responsible for 16000 deaths per year in Europe. The 
incidence of  COPD is related to tobacco smoking, and affects 20-30 million adults in 
Europe. Whilst levels are relatively static in men, they are rising in females following 
the increase in smoking in European women. It is estimated that COPD accounts for 
over 5% of  all deaths in Europe. 
4.2  It  is  likely  that  the  prevalence  and  diagnosis  of asthma  and  COPD  will 
continue growing in the EC  over the next decade. In addition, there is considerable 
potential for increased prescription of inhaled therapy for both conditions in a number 
of Member States as international treatment guidelines are implemented more widely 
than at present. For these reasons, IP AC has forecast that annual usage of  MD Is in the 
European Community may  increase  by  5%  per year between now and  2010.  This 
growth rate assumes that there will be increased usage ofDPis and other new types of 
non-MDI inhaler, as well as a potential increase in the use of newer oral therapies for 
some patients. 
4.3  There is international (WHO/GINA) consensus that the primary treatment of 
these diseases should be by the inhaled route.  This permits treatment to be delivered 
quickly  and  efficiently  to  the  airways,  with  minimal  risk  of adverse  reactions. 
Therapy necessitates regular treatment,  often with more than one medicine.  Inhaled 
therapy is delivered mainly by Metered-dose inhalers (MDis) or Dry Powder Inhalers 
(DPis) and less commonly by nebulisers. 
Categories of  drugs used for asthma/COPD 
4.4  It is possible to recognise the following categories of drugs currently used for 
the treatment of  asthrna/COPD: 
Category A: 
Category B: 
Category C: 
Category D: 
Category E: 
Category F: 
Short  acting  beta  agonist  bronchodilators,  such  as  salbutamol, 
terbutaline, fenoterol 
Inhaled Steroids, such as beclomethasone, budesonide, fluticasone, 
Non Steroidal anti-inflammatories, such as cromoglycate, nedocromil 
Anticholinergic bronchodilators, such as ipratropium, oxytropium 
Long acting beta agonists bronchodilators; salmeterol, formoterol 
Combination  products  containing  two  or  more  different  active 
substances 
4.5  It  is  important  to  realise  that  categories  A  and  B  combined  account  for 
approximately 80% of CFC MDis currently used in Europe.  For these categories A 
and B, there are several different active substances and alternative brands available for 
9 the  most widely prescribed products, but in  other categories there may be no more 
than one or two brands or products which require substitution by a non-CFC product 
MD Is 
4.6  The predominant form of inhaled therapy in most of Europe is the MDI which 
accounts  for  approximately  80%  of prescribed  inhalers.  The  remajJling  20%  are 
mainly DPis, together with a much smaller proportion ofnebulised drugs. However in 
some countries, especially Scandinavia and the Netherlands,  there is far greater use of 
DPis  (up  to  85%  ).  MDis  are  an  inexpensive,  reliable  and  effective  therapy  for 
respiratory diseases. Currently, some 500 million MDis are used annually world-wide, 
mainly  in  developed  countries.  Of these  approximately  200  million  are  made  in 
Europe requiring during 1997 the use of  some 6635 tonnes of  CFCs 
4.7  CFC-containing MDis have a forty  year record of safety and efficacy.  They 
are designed  to deliver drugs in an appropriate particle size to target the lung airways. 
Reproducing the particle size in reliable, safe and effective MDis without CFCs has 
proved to be a tough technical challenge. 
Alternatives to MDis 
4.8  Dry  Powder  Inhalers  (DPis):  Although  the  European  market  for  inhaled 
therapy  is  traditionally dominated  by  MDis,  almost  all  active  substances  are.  also 
available  in  DPI  formulations.  The  impending  ban  on  CFCs  in  the  1980's led  to 
considerable innovation in DPI technology and,  in particular,  to  the  transition from 
single-dose DPis to multidose systems. These  new-generation multidose DPis can, 
like MDis, deliver up to 200 doses. Multidose DPis are now quite widely available (as 
Turbuhaler,  Easyhaler and  Accuhaler,  for  example),  and  can  in  many  respects  be 
considered equivalent to MDis. 
4.9  As a result of  developments such as these, DPI use has increased, but since the 
overall use of inhaled therapy has increased further,  the greater use of DPis has not 
reduced  the  sales  of MDis.  Penetration  of DPis  into  a  market  depends  on  their 
acceptance  by  health  professionals  and  patients  and  also  on  their  cost.  In  some 
countries,  especially  S~andinavian  countries  where  action  has  been _  taken  by 
governments to  support the  transition from  MDis  to  DPis,  the  DPis dominate the 
market.  In  other  countries,  DPis  can  often  be  considerably  more  expensive  than 
cheaper generic  MDis.  A  complete  change  from  MDis  to  DPis  in  such  countries 
would increase the costs of inhaled medicines. New DPis are likely to be introduced 
over the next few years which may be cheaper and will increase patient choice. DPis 
may become an increasingly appropriate and accepted alternative for MD Is, especially 
for new patients, although they are not suitable for all patients (for example some very 
young children may experience difficulties). Nevertheless, the wide range of available 
DPis provides  a  safety back-up  during  transition  to  CFC-free  MDis  and  provides 
additional options for patients. 
4.10  As far as DPis are concerned, products are already available in each category 
such as the following: 
10 Category A:  Salbutamol  (Diskhaler™, 
terbutaline (Turbuhaler™) 
Diskus™,  Rotahaler™,  Easyhaler™); 
Category B:  Beclomethasone (Rotahaler, Diskhaler, Easyhaler);budesonide 
(Turbuhaler); fluticasone (Diskhaler) 
Category C:  Cromoglycate (Spinhaler) 
Category D:  lpratropium(Aerohaler) 
Category E:  Salmeterol(Diskhaler, Diskus, formoterol(Turbuhaler, Aerolizer) 
This suggests that, subject to  greater acceptance by doctors and patients, and given . 
sufficient manufacturing capacity, there may be scope for an increase in the numbers 
of patients treated by  DPis rather than by  MDis.  This of itself would contribute to 
reducing the current use of  CFCs in the treatment of  asthma and COPD. 
4.11  Nebulisers:  These  devices  produce  aerosols  by  agitation  of solutions,  and 
account for 1-2% of  the market. They are generally reserved for patients with special 
needs,  such as  very  young  babies or patients with severe disease,  who  need  much 
higher doses of active  substance.  They are  currently an  expensive  form  of inhaled 
therapy, but new devices may make this a more viable option in the future. 
4.12  New  Oral Therapy  A novel tablet (leukotriene modifier) for the treatment of 
asthma is currently under regulatory review in Europe. This type of oral therapy may 
be of value to some asthma patients, but is  highly unlikely to  become a significant 
substitute for  the current inhaled preventative therapy.  The  mainstay  of therapy for 
asthma/COPD is likely to remain that administered by the inhaled route. 
MDis Reformulated Without CFCs 
4.13  As  a  result  of a  major  research  and  development  effort,  pharmaceutical 
companies have made good progress in developing CFC-free MDis.  In March 1995, 
Europe's first  approval  for  a CFC-free MDI  was  granted to  3M  in the  UK  for  its 
product 'Airomir', a salbutamol product reformulated with HFC-134a propellant.  By 
September 1997, this product had been approved for use in o-ver 40 countries and in 
nearly  all  the  Member  States  of the  European  Community  Glaxo  Wellcome  has 
recently  launched  CFC-free  versions  of  'Ventolin'  (salbutamol)  and  the  first 
reformulated inhaled steroid 'Flixotide' (fluticasone) in some Member States.  Other 
companies have also submitted applications to market CFC-free inhalers, and further 
approvals are anticipated during 1998 and beyond. It is therefore expected that, during 
the course of 1998,  two  salbutamol CFC-free MDis will be  become  available  in  a 
number of  countries, including a number of  EC Member States. 
4.14  IP AC  (International  Pharmaceutical  Aerosols  Consortium)  predicted  in 
January  1997  that,  in  Europe,  between 36  and 42  HFC  MDI  'entities'  (individual 
dosage formulations of  individual brands) would be reformulated and launched by the 
year  2000.  It is  anticipated that at  least two  salbutamol  CFC-free  MDis  could be 
available throughout the EC by the end of 1998. Since salbutamol MDis are estimated 
II to comprise half the total use of MD  Is, the potential exists for a significant reduction 
in  consumption  of CFCs  in  1999.  This  is  dependent  on  regulatory  and  pricing 
approval, good acceptance and uptake by patients and physicians, and the consequent 
timely phaseout of CFC inhalers. In addition, two or more CFC-free inhaled steroids 
should be available in some Member States by  1998. Reformulation efforts for  most 
of the remaining inhaled medications are well advanced, using the propellants HFC-
l34a and HFC-227.  Alternative technologies  such as  portable  hand~eki nebulisers 
are also being evaluated. 
Experience to date 
4.15  Almost two years after the introduction of the first CFC-free salbutamol MDI 
into  the  European  Community,  it  had  only  reached  1.5%  market  share.  Factors 
influencing  the  slow  uptake  of this  CFC-free  product  might  include  lack  of 
incremental  benefit  to  patients,  apathy  of physicians  to  envirorunental  benefits, 
continued easy availability of CFC-products  and  higher cost than  unbranded  CFC 
salbutamol  products.  Experience  in  Germany  with-a second  CFC-free  salbutamol 
product  is  more  encouraging.  Three  months  after  the  laimch  it  has  achieved 
considerable success, but to' maintain the growth in uptake, the manufacturer intends 
voluntarily to withdraw the CFC version. However, it is unlikely that voluntary action 
by manufacturers and education programmes alone will produce a significant switch 
away  from  CFC  products  in  the  absence  of  a  clearly  defined  and  properly 
implemented transition policy. This needs to  be accompanied by  a clear message to 
physicians and other health professionals that the transition is  not optional.  Where a 
CFC-free alternative is available and suitable,  it should be prescribed in favour of the 
CFC product unless this would compromise patient treatment. 
Considerations in devising a transition strategy 
4.16  A  number  of  factors  have  been  considered  when  developing  a 
European transition strategy. In particular, before the use of CFCs can be  phased out 
in the manufacture ofMDis: 
•  A sufficient number of clinically effective, technically and  economically feasible 
alternatives  (including  DPis)  needs  to  be  available  to  ensure  an  uninterrupted 
supply ofmedication. 
•  A sufficient period of  post marketing surveillance of the reformulated products has 
to be carried out 
•  There needs to be sufficient choice of alternatives available to  meet the  needs of 
different patient sub-groups 
12 Chapter 5  DEVELOPING ALTERNATIVES TO CFC-CONTAINING MDis 
Current treatment by inhalation: MD  Is, DPis and nebulisers 
5.1  The  three  main  types  of inhaled  treatment  for  respiratory  disease  include 
MDis, DPis and nebulisers. Each type presents certain advantages and disai:lvantages. 
Efforts are being made to overcome disadvantages, for example by impraving powder 
delivery in DPis to facilitate their use by small children and the elderly.  However, 
nebulisers and DPis are not interchangeable with MDis for all patients.  It is vital to 
develop CFC-free MDis with the same advantages for patients as the current CFC-
containing MDis but without the disadvantage of  depleting the ozone layer. 
Developing non-CFC MDis 
5.2  The pharmaceutical industry has put significant resources into researching and 
developing  CFC-free  MD Is.  More  than- 70  separate  programmes,  involving  I ,400 
scientists and 90 laboratories in 1  0 countries around the world, have been involved in 
reformulating MDis with alternative propellants.  Investment to  date in this task by 
the pharmaceutical industry worldwide exceeds 1 billion ECUs. 
5.3  The  first  step  in this  research  was  to  identify  propellants  which  could  be 
substitutes for CFCs.  The principal criteria for  successful MDI propellants are  the 
following: 
•  a liquefied gas of  very low toxicity, non-flammable and chemically stable 
•  acceptable to patients in terms of  taste and smell 
•  possessing appropriate solvent characteristics and a suitable density. 
Other  considerations  include  sufficient  commercial  availability  of the  proposed 
propellant, whether it can be made sufficiently pure for  pharmaceutical use,  and  its 
continued future availability in quantities sufficient to meet patient needs. It has been 
extremely difficult to identify a single compound which meets all of  these criteria. 
5.4  After extensive research, 
1 HFC 134a and HFC 227 have been identified as the 
only real alternatives to CFCs for MDI use. They are non-flammable, safe for human 
inhalation and have the required vapour pressure and density for MDI usage. HFCs 
have zero ozone-depleting potential, but both HFC 134a and HFC 227 are greenhouse 
gases and part of the basket of gases whose emissions must be reduced under the 
Kyoto  Climate Change  Protocol.  However,  both these  HFCs have  a  lower global 
warming potential (GWP) than the CFCs which they replace. For example, HFC 134a, 
the most frequently chosen replacement propellant, has a GWP of 1300, compared 
with CFC 12 which has a GWP of 8500. Note that, as a point of  reference, the GWP 
of C02 is  1.  Therefore, a change from  CFCs to  HFCs as  propellants in MDis will , 
Studies have been carried out to  determine  whether  any  compounds  other than 
HFCs could be substituted for CFCs in MDI usage.  Some 1  5,000 compounds have 
been reviewed in light of  the various criteria set out above but none of them, with 
the exception of  HFCs, appears to be a promising CFC substitute. 
13 contribute  to reducing  both ozone  depletion  and  greenhouse  gas  emissions  in  the 
future.  Nevertheless, there remains  scope to continue research  into  products which 
have even less environmental impact. 
5.5  Once identified as possible CFC substitutes on the  basis of their chemical 
characteristics,  HFCs were subjected to  extensive research and testing.  In January 
1989, the pharmaceutical industry set up  its own consortium (uitimatety known as 
IP AC), and began toxicology testing of propellants for phannaceutical usage. These 
testing programmes, designed to meet world-wide regulatory requirements, including 
those of  the US, the EC and Japan, were substantially completed by the end of 1995, 
and concluded that both HFC-134a and HFC-227 were safe for use in MDis.  The 
Committee on Proprietary Medicinal Products (CPMP) of the European Community 
assessed both propellants as suitable alternatives for  CFCs (in July  1994 for HFC-
134a and in September 1995 for HFC-227), subject to completion of  additional safety 
studies on the medicinal products concerned. 
5.6  Having identified HFCs as the best alternative to CFCs and shown that they 
have. no adverse toxicological effects,  the second step was  for  the pharmaceutical 
industry to reformulate their MDis using these propellants.  In the EC, the European 
Commission  has  published  guidelines  on  the  replacement  of CFCs  in  medicinal 
products
2
• These identify the questions of product efficacy, safety and quality which 
must  be  taken  into  account  by  companies  when  they  prepare  submissions  for 
marketing authorisation of  products containing alternative propellants.  A guideline on 
post-marketing surveillance has also been prepared (CPMP/180/95). 
5.7  The  reformulation  effort  has  involved  several  steps  in  order to  fulfill  the 
regulatory guidelines and create replacement products which are comparable in all 
respects to the existing ones.  First, there is intensive research and testing to identify 
and develop new formulations' of the active anti-asthmatic drugs with the new HFC 
propellants.  Such formulations have to meet rigorous  quality criteria,  for example, 
with  respect to  accurate  dose reproducibility throughout the  life  of an  MDI,  and 
maintenance  of a  consistent  particle  size  distribution  in  the  spray.  -Next,  the 
components of the primary packaging (metal cans, valves, elastomers and actuators) 
have to be redeveloped to be compatible with the new propellant and formulation. 
Toxicological studies are carried out on the final formulation (which possibly contains 
new inactive ingredients) before, or in parallel with, stability testing of  the new MDI. 
The latter is undertaken to ensure that quality is maintained over the entire shelf-life 
of  the new product.  Finally, clinical studies are carried out on the new product, over 
a treatment period of up to one year, to demonstrate that it is as safe and effective as 
the CFC product. 
2  Note for Guidance Replacement of  Chlorofluorocarbons (CFCs) in metered-dose 
inhalation products (11115378/93 -final). CPMP Cover note- Matters relating to the 
replacement ofCFCs in medicinal products (III/5462/93- final rev.l 
14 Difficulties enconntered in reformulating MDis 
5.8  The reformulation of CFC  MDis has  proved  to  be  much  more technically 
difficult than originally envisaged.  In addition to the complexity of identifying and 
testing alternative propellants, the pharmaceutical industry has encountered a number 
of other challenges in  its refonnulation efforts.  For example, the usual surfactants 
used  in  CFC  MDis  are  generally  not  compatible  with  HFCs.  NeW' surfactants; 
lubricating agents and co-solvents had to  be  identified.  Some valve elastomers are 
affected by HFCs and do not function with sufficient reliability so new elastomers had 
to  be  developed.  In  some  cases  actuators  had  to  be  redesigned  together  with  the 
manufacturing process to accommodate the more volatile HFC propellants, sometimes 
involving  building new manufacturing  facilities  and  finding  new manufacturers of 
components. 
5.9  It is  only  after  reformulation  and  clinical  testing  have  been  successfully 
completed that the regulatory review phase can begin, encompassing pharmaceutical 
safety  and efficiency  assessments of the  data submitted  by  companies  against  the 
guidelines described earlier.  A new marketing authorisation would be required from 
the appropriate regulatory authorities, where the MDI is fundamentally altered by the 
change in propellant and modifications to the formulation and manufacturing process. 
Where the change is not fundamental;  a national variation procedure may be used. 
Efforts are ongoing t6 enable CFC-free MDis to be approved as rapidly as possible by 
all the Member States of the EC (see Chapter 6).  Regulatory authorities must also 
review  pricing  and  reimbursement  of CFC-free  MDis,  as  price  differentials  can 
significantly influence acceptance by patie1:ts and prescribers. 
Prioritizing reformulation efforts 
5.10  Although the decision to reformulate a specific MDI product is taken by each 
individual pharmaceutical company in respect of each of its CFC MD  Is, the priorities 
are  common throughout  the  industry.  In  general,  each  company  has  focused  its 
reformulation efforts on the MDI products which are the most commonly prescribed 
and which use the most CFCs.  Products which are used less frequently are the second 
priority, even though these MDis may be important for certain patient sub-groups. 
5.11  In addition to the above considerations, the phitrmaceutical industry is limited 
by the technical feasibility of  refonnulating MD  Is. Particular molecules and/or dosage 
strengths may be more difficult than others to reformulate. Failure to satisfy product 
quality criteria fully could necessitate multiple attempts at reformulation and testing. 
Important products which are given a high priority could therefore still take time to 
come through the development pipeline. 
Strategy/risk analysis for products which are not reformulated 
5.12  Some products may not be reformulated for economic reasons  while others 
may ultimately prove impossible to reformulate for technical reasons. It is important 
to note that Decision VIII/I 0 of the  Parties to the Montreal Protocol requires  that 
companies  applying  for  continued  essential  use  of  CFCs  for  MDis  should 
15 "demonstrate ongoing research and development of  alternatives with all due diligence 
and/or collaborate with other companies in such efforts., Therefore,  CFCs will  not 
continue  to  be  available  to  MDI  companies  which  are  not  actively  engaged  in 
developing and marketing CFC-free alternatives. After .the bulk of the transition to 
non-CFC MDis is  accomplished, the  Commission and Member States will  need to 
assess whether any remaining CFC-containing inhalers are still essential, for example 
because there is no other way to meet the medical requirements of pariicular patients. 
Where  they  are  not  essential,  physicians  and  patients  will  have  to  switch  to  an 
alternative  treatment  within  a  reasonable  time-frame.  Where  they  are  essential,  a 
mechanism for continuing but temporary supply will need to be found. Note that there 
can be no long-tenn dependency on CFCs as both the propellant and the products will 
progressively disappear from the market. 
Naming, packaging and identifying the alternatives 
5.13  Decision VIIUlO. (3) of  the Parties to theMontreal Protocol states that the GFC 
and non-CFC products must be differentiated in tenns of packaging and marketing. 
To ensure a smooth transition from CFC-containing MDis to CFC-free MDis and for 
maximum  transparency,  it  has  been  agreed  that  CFC-free  products  will  be 
differentiated from CFC-containing ones. This should be done by changing the brand 
name or by adding a logo or "flash" to the existing packaging to indicate clearly that 
the product is CFC-free.  CFC-free products should also include a leaflet to explain 
about the new propellant and the reasons for change.  This differentiation is  vital to 
post-marketing safety monitoring so that any reported adverse effects can correctly be 
attributed to the type of  product concerned. 
5.14  D~rective 92/27/EEC  sets  out the  normal  procedure  whereby  the  proposed 
labeling for medicinal products is submitted to the appropriate regulatory authorities 
with  the  application  for  marketing  authorisation.  Pharmaceutical  companies  will 
decide  whether they  wish to  retain the. existing  brand name  and  adapt  its  existing 
labeling, including the addition of the term "CFC-free, or to  introduce a completely 
new brand name for the non-CFC MDI.  These provisions should ensure that CFC-
free  MDis  are  appropriately  and  adequately  differentiated  from  CFC-containing 
MD Is. It would also be useful for the name and characteristics of the propellant used 
to be written on the container. 
Forecasts of  future availability of  alternatives 
5.15  It is  difficult  to  forecast  with  any  certainty  the  dates  by  which  CFC-free 
versions of particular products will be available on the  Community market.  At the 
beginning of 1996, IPAC forecast that there would be between 36 and 42 HFC MDis 
launched on the European market by the year 2000. However, that forecast has since 
been  revised  downwards  in  light  of technical  problems  some  companies  have 
encountered with reformulations and unanticipated delays in the  granting of market 
authorisations.  To  try  to  obtain  some  more  recent  information,  the  Commission 
recently asked MDI manufacturers in the Community to forecast when they planned 
to  submit  applications  for  marketing  authorisation  for  CFC-free  versions  of their 
current  CFC  inhalers.  The  results  indicate  that,  by  the  year  2000  we  can  expect 
16 companies to  have submitted applications for  marketing authorisation for  CFC-free 
versions of  over 30 different MDI products. This does not include different strengths 
or dosage versions of  the same active substance. 
A  Summary  of planned  dates  reported  by  companies  for  filing  of marketing 
authorisation in the  European Community  for  selected  active  substances  is  shown 
below. Not all the details can be given for reasons of  commercial confuierttiality. 
Active Substance  First  Last  When product is 
mentioned  mentioned  likely to lose 
filing date  filing date  essential use status* 
Salbutamol  1994  2001  1998-1999 
Terbutaline  2000  2004  2001-2002 
Fenoterol  1998  2002  1999-2000 
Beclomethasone  1996  2002  1999-2000 
il  udesonide  20QO  2002  2001-2002 
Cromoglicic Acid  1998  1999  1999-2000 
lpratropium Bromide  1999  2000  2000-2001 
• penod dunng whtch CFCs for a particular product are likely to lose thetr essential use status m some 
or all  of the  Member  States  under  the  provisions  of this  strategy  if the  granting  of marketing 
authorisations for the CFC-free alternatives is not unduly delayed. 
5.16  The survey indicates that some companies are expecting to file  applications 
after  a  CFC  product  is  likely  to  have  lost  its  essential  use  status.  For example, 
Salbutamol is likely to be available throughout the Community in CFC-free versions 
by the year 2000.  CFCs for the manufacture of salbutamol would not then meet the 
essential uses criteria in 2000 and none would be approved. This may pose problems 
for  the  few  companies  which  expect  to  submit  their  application  for  marketing 
authorisation ofthe CFC-free alternative in 2001. 
5.17  It  should be emphasised that even with questionnaire surveys like this, it is not 
possible  to  predict  with  any  certainty  how  quickly  the  alternatives  will  become 
available and therefore how quickly the demand for CFCs will fall. Much depends on 
how quickly  and  efficiently  Member  States  grant  marketing  authorisation  for  the 
alternatives. When taking decisions on quantities of CFCs to approve, it will remain a 
priority to ensure. that patients continue to have access to the medicines they need .. 
17 CHAPTER6  APPROVAL  OF  NEW  PRODUCTS  and  POST-
AUTHORISATION SURVEILLANCE 
6.1  At their November 1996 meeting in Costa Rica, the Parties to the Montreal 
Protocol  agreed  "to  request  national  authorities  to  expedite  review  of 
marketing/licensing/pricing  applications  of CFC-free  treatments  of asthma  and 
COPD, provided that such expedited review does not compromise patient health and 
safety"  (Decision  VIII/11).  A  clear  statement  of how  this  decision  is  to  be 
implemented in the EC is an important part of  this phaseout strategy. In particular, the 
strategy identifies marketing authorisation procedures which will ensure the earliest 
possible introduction of CFC-free MDis.  The  availability of CFC-free products to 
patients in the EC should not be delayed by slow, repetitive procedures for obtaining 
marketing  and  pricing  authorisation  independently  in  each  Member  State  of the 
Community. 
Co-operation between Member States 
6.2  Recognising the large number of CFC-free products which may be submitted 
to  Regulatory  Authorities  over a relatively  short  time  period,  it  is  in the  general 
interest of  Member States to co-operate and share the workload of  review. Procedures 
for reviewing replacemen~ for existing CFC products and approving new CFC-free 
products should include at least the following elements: 
•  that companies should submit applications  across  the  whole  of the  Community 
simultaneously 
•  that competent authorities should co-operate in sharing out the work and its results 
•  that CFC-free products should be authorised for use without delays and, as far as 
possible, simultaneously across the Member States. 
In addition, Member States should ensure that their procedures for agreeing pricing 
and reimbursement do not cause unnecessary delays to the  availability of CFC-free 
medical  inhalers  on the  European  market.  Decision  VIII/11  of the  Parties  to  the 
Montreal Protocol requests national authorities "to review the  terms for public MDI 
procurement  and reimbursement ·  so  that purchasing policies  do  not discriminate 
against non-CFC alternatives". ManufactUrers of alternatives can assist this process 
by  pricing their CFC-free products at similar levels to  the  CFC  products they are 
intended to replace. 
6.3  Although  it  is  important  to ensure  that  CFC-free  products  are  brought  to 
market quickly, this should not compromise patient safety. The prime objective of  the 
review and approval procedures is to ensure that products submitted for approval meet 
all the necessary standards of  quality, safety and efficacy. 
18 6.4  There is a number of possible routes to  obtain marketing authorisation in the 
European Community for CFC-free MDis. Further details are shown on I:igure 1. 
•  A  referral  under Article  12  of Council  Directive  75/319/EEC:  this  is  the 
preferred  route  in  order  to  gain  access  to  the  entire  Community  market.  The 
Commission considers the rapid and safe replacement of CFCs  in MDis to  be a 
matter  of Community  interest.  Therefore,  if other  procedures ..faH  to  operate 
successfully,  the  Commission  reserves  the  right  to  use  the  Article  12  referral 
mechanism as a means to expedite the evaluation of marketing authorisations for 
reformulated CFC-free MDis. 
•  a Centralised Procedure, as set out in Council Regulation (EEC) No. 2309/93: 
this  includes  submission of the  application to  the  EMEA  (European  Medicines 
Evaluation Agency), scientific evaluation and opinion by the CPMP (Committee of 
Proprietary Medicinal Products), and a Commission Decision granting a marketing 
authorisation valid for the entire Community market.  CFC-free MDis containing 
new active substances are eligible for evaluation under this centralised procedure 
only if  they comply with part A or part B of  the annex to the Regulation. 
•  a Mutual Recognition Procedure: this involves submissions to all Member States 
which  need  to  place  the  CFC-free  MDI  on their market.  One  Member  State 
prepares  a  scientific  evaluation  and  grants  marketing  authorisation  for  its  own 
territory.  The  other  Member  States  recognise  the  decision  and  grant  their  own 
national marketing authorisation. 
•  an  ad-hoc  co-operation  mechanism  agreed  between  the  Commission  and 
Member States: this will enable a series of national marketing authorisations to be 
granted quickly by promoting the mutual'sharing of information and work among 
Member States. 
6.5  From  1  January  1998,  the  mutual  recognition  procedure  applies  for  new 
applications for  the  same  medicinal product in  more  than  one  Member  State.  For 
"stand-alone" applications (i.e. those made in accordance with Articles 4.8 or 4.8 (a) ii 
of Council Directive 65/65/EEC  as amended),  the  mutual recognition  procedure  is 
mandatory.  Even when  a  company  does  not  request  mutual  recognition,  Member 
States will recognise decisions of  other Member States for the same medicinal product 
where the same application is submitted in all concerned Member States. 
6.6  ·Where the ad hoc co-operation mechanism is used, two situations can apply; 
a)  where the company wishes to  use a different brand  name  or  to  introduce  a 
second  product  which  is  CFC-free.  Under  these  circumstances,  an  abridged 
application (cf  Article 4.8 (a) (i) of  Directive 65/65/EEC) should be submitted. 
b)  where the company wishes to retain the same brand name with the addition of 
a flash "CFC-free". Under these circumstances, a submission in the form of a national 
variation, should be submitted. 
19 Note that if reformulation results in changes to  the  content per actuation or dosing 
schedule  or includes  a  quantitative  change  in  the  active  substance  or a  change  in 
bioavailability, then the application could not be classified as a variation but should be 
submitted as  an  abridged  application.  (  cf Annex  II  of Commission  Regulation  on 
Variations to the terms of  a marketing authorisation, (EC) No. 541/95) 
6.7  Whether or not  the  submission  is  made  as  an  abridged  apJ*ication  (a)  or 
national variation (b), the agreed procedures are very similar. 
The applicant: 
a)  - provides a list of the Member States in which the same abridged application or 
variation has been submitted or will be submitted in parallel and, in the latter case, 
the  dates  at  which  the  applications  are  planned  to  be  submitted.  Note  that 
companies should simultaneously submit the information to all the Member States 
where authorisation is going to be required. 
b)  includes a commitment that he has submitted or will submit exactly the same data 
package to each Member State 
c)  provides copies of the current and proposed new labelling to  allow review of the 
information to  be  provided  on the  replacement  and  to  ensure  that  patients  will 
receive sufficient detailed information 
d) provides  a  draft  Summaries  of Product  Characteristics  (SPC)  of the  CFC-free 
product  consistent  with  SPC  of the  CFC-containing  product  it  is  intended  to 
replace,  including  all  relevant  details  of  the  replacement  so  that  health 
professionals will receive complete information. 
The Member States: 
a)  One Member State prepares an assessment report on the abridged application or the 
variation 
b)  as soon as the assessment is completed, the Member State circulates the assessment 
report to other Member States listed in the applicant's dossier. 
c)  based on their own assessment or assessment report(s) circulated by other Member 
States,  will  grant  the  authorisation  or  variation  and  issue  the  marketing 
authorisation within a period of 180 days. To expedite this process, all usual forms 
of contact between Member States will  have  to  be  used,  including phone  calls, 
ancillary information requests on the assessment report, answers to requests etc 
d) inform other Member States of the date at which the variation to the terms of the 
marketing authorisation has been granted. 
e) prepare a schedule for  substituting the  CFC-containing product by the CFC-free 
product. This substitution process should not exceed twelve months, which allows 
adequate time for post-marketing surveillance of  the CFC-free product. 
20 f)  keep the Commission and the EMEA informed by sending details on the approvals 
granted, active substance by active substance, and on the progress of substituting 
CFC-containing products by CFC-free products in their territories. 
The European Commission  · 
For both abridged applications and national variations, to facilitate the eentralisation 
of  data for the Community as a whole, the Commission requests the EMEA to keep an 
up to date list of  the submissions received and approved for each active substance in 
each Member State; and the rate of  progress of substituting CFC-containing products 
by CFC-free products in each Member State. 
Post Authorisation surveillance and safety studies 
6.8  The legal framework for pharmacovigilance of medicinal products for human 
use in the Community is given in Council Directive 75/319/EEC. Detailed guidelines 
on pharmacovigilance are  included in Volume  9 of the  Rules  governing medicinal 
products for human use in the European Community. 
Safety Issues relating to new products 
6.9  When  products  are  marketed,  their  use  may  include  patient  groups  which 
differ in various respects from those represented in clinical trials performed prior to 
issuing or varying of  a MA.  How products are prescribed and how patients use them 
will also differ from the clinical trial situation.  Clinical trials designed to demonstrate 
efficacy of the new products  for  authorisation  are  frequently  not  large  enough  to 
detect rare side effects. For these reasons intensive post-authorisation surveillance is 
critical in confirming the safety of  new CFC-free products. 
6.10  Safety  issues  possibly  relevant  to  the  introduction  of CFC-free  products 
include paradoxical bronchospasm and rare adverse effects from the new excipients. 
New formulations may result in altered lung deposition and hence bioavaitability. For 
this  reason  the  occurrence  of  significant  systemic  adverse  reactions  to  the 
reformulated products may differ considerably from the equivalent CFC- containing 
product.  In  addition,  changing  from  CFC-containing  to  CFC-free  products  could 
result in short-term deterioration in disease control for some patients. Long-term use 
of CFC-free inhaler devices will  occur following  marketing,  and their performance 
will need to be established.  · 
6.11  Intensive  post-authorisation  surveillance  will  be  needed,  with  regulatory 
authorities and MA holders working in close partnership. Doctors and pharmacists can 
also play a useful role in evaluating the success and safety of CFC-free inhalers as 
their use increases. 
Phase Out Time Of  CFC- Containing Products 
6.12  CFC-containing products  should  be  phased  out quickly,  so  the time that  a 
CFC-free  product  and  it's  equivalent  CFC-containing  product  will  be  available 
21 concurrently is limited. Sufficient time needs to be available for data collection. It has 
been agreed that, normally, the CFC product could remain available in the market for 
up to twelve months following launchof the replacement product.  During that time,_ 
MA holders and pharmacies will run down stocks of the CFC product as take up of 
the replacement product increases:' Any safety issues with the CFC-free products will 
need to be rapidly identified, evaluated and acted on so that they are resolved before 
the  equivalent  CFC-containing  product  is  finally  withdrawn.  MA .holders  should 
prepare plans  so  that, if important safety  concerns  arise  relating to their CFC-free 
product,  they  will  be  able  to  supply patients  with  an  equivalent  CFC- containing 
product. 
Spontaneous Adverse Drug Reaction Reporting 
6.13  The requirements for MA holders to report spontaneous adverse drug reactions 
are set out in Directive 75/319/EEC.  No change in these requirements is necessary for 
CFC-free products. 
Post-Authorisation Studies 
6.14  A guideline for post-marketing surveillance of  new CFC-free inhalers has been 
prepared
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•  MA holders are encouraged to  perform large  safety studies of CFC-free 
products.  These  studies  will  usually  include  comparisons  of CFC-free  and  CFC-
contain.ing  inhalers  following  a  randomised  clinical  trial,  or  observational  cohort 
design. The use of single-dose studies should also be considered. The trials should be 
set  up  in  such  a  way  that  it  is  clear  that  the  patients  who  complete  them  are 
representative of  the whole patient population, including children and the elderly. The 
study design may encompass an assessment of the changeover from the original CFC-
containing product to the CFC-free product. 
6.15  Adverse  event  and  haematological  and  biochemical  monitoring  should  be 
undertaken in all  safety studies, together with specific assessments, pertinent to  the 
drug substance, to look for local and systemic effects which might not necessarily be 
recorded as, or manifest themselves as, adverse events (e.g. adrenal suppression with 
inhaled corticosteroids). 
6.16  MA holders will submit proposals to  the regulalory authority to monitor the 
introduction of  the CFC-free products in order to identify rare and unexpected adverse 
effects.  A method such as the use of  record linkage schemes should be considered, as 
this could provide a means  for  monitoring the  CFC-free products  against historical 
data relating to the products using CFC propellants.  Careful observation of patients 
and  a  specific  assessment  of  cough,  wheezing  and  bronchospasm  on  first 
administration of the product, paying particular attention to  the time to onset of any 
effect,  would  be  useful.  Specific  questioning  and  assessment  of paradoxical 
bronchospasm would be appropriate in single-dose studies and after the first dose of 
each limb in crossover studies. 
3 EEC/180/95 
22 Liaison with regulatory authorities 
6.17  Companies proposing to perform a post-authorisation safety study are advised 
to  discuss  the  draft  protocol  with  the  relevant  regulatory  authorities  when  the 
application for a MA or variation is made.  Particular consideration should be given to 
specific  safety  issues  which  may  require  investigation.  National  legislative 
requirements  or guidelines  should  be  taken  into  account  in  those  Member  States. 
where these exist. 
6.18  A final report on the study should be sent to the relevant regulatory authorities 
within 1 month of  follow-up being completed.  Ideally this should be a full report but 
a preliminary report within  1 month,  followed  by  a full  report within 3 months of 
completion of the study  would normally  be  acceptable.  The  findings  of the study 
should be submitted for publication. 
23 Figure 1:  POSSIBLE ROUTES TO APPROVAL 
Route 1:  Referral under Article 12 of Council Directive 75/319 (EEC) 
Route 2:  Referral under the centralised procedure of Council Regulation 
No. (EEC) 2039/93 
Either Route 3 or Route 4 depending on whether or not the brand name changes 
(ROUTE 3) 
I 
I  unchanged  I 
purely 
national procedures 
procedures for 
variations to 
national MA or 
abridged application 
proposed ad- hoc 
procedure 
fNational MA  I 
(ROUTE4) 
I 
changed  I 
~~ 
~~~~----~  ~~--~~----~ 
in one  in more than 
Member State  one Member State 
MA 
National 
Procedure 
in future, 
provisions of 
Chapter III of 
D.75/319 
applicable if  product 
is to be marketed in 
other Member States 
MA 
decentralised 
procedure 
Mutual 
Recognition 
Procedure 
Article 9, D75/319 
Article 7a, D65/65 
harmonised MA 
decentralised 
procedure 
In practice, the approval pro  edures in route 4a and 4b rely on the initial dossiers 
(pseudo-abridged application) with two conditions: a) all the initial dossiers have to 
be identical and updated b) initial dossier to be completed, where necessary, with 
additional information including (Council Directive No 75/318(EEC)) parts II and/or 
III and/or IV (in particular biodisponibility.) 
24 CHAPTER 7  PHASING OUT CFCs 
Possible approaches to the CFC phaseout 
7.1  The essential use exemption for CFCs in MDis cannot continue indefinitely. 
As  alternative  propellants  become  available,  together  with  alternative  methods  of 
treating  asthma and  COPD,  CFCs will progressively  be  withdrawn.. Based on the 
expected rate of development and timely  approval  of alternatives,  it is  likely  that 
many metered dose inhalers used in the European Community will be CFC-free by 
2000. 
7.2  During this transition period it is vital that patients continue to have access to 
the  medicines  they  require.  At  the  same  time,  it  is  necessary  to  ensure  that  the 
production and use of CFC-containing MDis declines at a rate consistent with the 
introduction of  alternatives. Balancing these two imperatives requires a clear strategy. 
This strategy sets out the circumstances and procedures under which any new CFC-
free  inhaler  will  be  determined · to  be  a  technically  and  economically·  feasible 
alternative  or  substitute  for  one  or  more  existing  CFC-containing  products.  The 
strategy also specifies the mechanism and timetable for the withdrawal of CFCs from 
the manufacturing process once satisfactory alternatives are available and advice on 
how to deal at that stage with stocks of  CFCs and CFC-containing inhalers. 
7.3  Some useful information on CFC phaseout strategies has been provided by the 
Aerosols, Sterilants, Miscellaneous Uses and Carbon Tetrachloride Technical Options 
Committee of the Montreal Protocol in their April 1997 report. The committee notes 
that the following  points  should be  considered  when  developing  a  CFC  phaseout 
strategy: 
•  there  ~hould  be  sufficient  technically  and  economically  feasible  alternatives 
available to assure an uninterrupted supply of  medication 
•  one or more separate formulations of the same therapeutic substances need to be 
available 
•  there should be sufficient post marketing surveillance of  the reformulated products 
•  there  should be  sufficient  choice  of alternatives  to  meet the  needs  of different 
patient sub-groups 
•  sufficient time and resources should be available for educating health professionals 
and patients 
•  companies manufacturing CFC products must be committed to reformulation 
•  the strategy should be consistent with the relevant legal and economic framework 
covering such things as approval, registration and pricing of  medicines 
7.4  In addition to these general points, the Technical Options Committee report 
sets out four possible approaches to designing a strategy for the phaseout of CFCs in 
metered dose inhalers. These include: 
1) Phasing  out  CFCs  brand  by  brand:  With  this  approach,  when  a  company 
produces a new or reformulated product which replaces its CFC product, it would 
be  required  to  introduce  the  new product  and  phase  out  the  old over  a  given 
25 timescale. The timescale would be consistent with the company's production and 
distribution capacity and reasonable post-marketing surveillance. 
2) Phasing out CFCs active substance by active substance:  With this  approach, 
once a CFC-free MDI containing a particular active substance (eg salbutarnol) had 
been launched and satisfactory post-marketing surveillance data obtained,  CFCs 
would be withdrawn for all MDis containing that particular active substance and, 
after a given period,  licenses for  the further  sale of the  CFC  pro"tluct  would  be 
withdrawn 
3) Phasing out  CFCs  category  be  category:  With  this  approach,  existing  CFC 
products are grouped into categories according to the type of disease being treated 
or the way the active substance operates.  The categories are as follows: 
Category A:  short-acting beta agonist bronchodilators (eg salbutamol) 
Category B:  inhaled steroids (  eg beclomethasone) 
Category C:  non steroidal anti-inflammatories (eg cromoglycate) 
Category D:  anticholinergic bronchodilators (eg ipratopium) 
Category E:long acting beta agonist bronchodilators (eg salmeterol) 
Category F:combinations 
For each of  the categories (A) to (F), when sufficient CFC-free alternatives become 
available  in  that  category,  all  the  remaining  CFC-containing  products  in  that 
category can be phased out. What is defined as a "sufficient" number of CFC-free 
products  will  vary  from  category  to  category  according  to  the  importance  and 
extent of  use of  the products concerned. 
4) Phasing out CFCs according to targets and timetables: With this approach, the 
strategy would set targets for CFC reduction to zero over a given time period, in 
line with the expected availability of CFC-free alternative products or treatments. 
The  timetable  could  be  reviewed  regularly  and  amended  in  the  light  of actual 
progress in the development and launch of alternatives.  Under another variant of 
this approach, the strategy might simply plan to reduce the availability of CFCs by 
a given percentage each year (eg 20% cut each year to zero over 5 years), leaving 
manufacturers, doctors and patients to find ways to work successfully within these 
limits. 
7.5  Among these  different options,  different  strategies  might  be  appropriate  to 
different circumstances. When it comes to selecting the most appropriate strategy for 
the EC, it is useful to consider the criteria which it must meet to be successful.  These 
include: 
•  phasing out CFCs as soon as reasonably possible 
•  ensuring that patients continue to have access to necessary medicines 
•  being clear, equitable, consistent and transparent 
•  being understood and supported by doctors and patients 
•  setting a clear direction to allow future planning with confidence 
•  being able to reflect the different circumstances of  each Member State 
26 7.6  If patients  are  to  continue  to  have  access  to  the  medicines  they  require, 
including where necessary a choice of  suitable therapies, it will be important to ensure 
that CFCs are not withdrawn prematurely before adequate alternatives are available. 
In  this  context,  'availability'  will  mean  sufficient  manufacturing  and  distribution 
capacity, together with evidence of  the effectiveness of  the alternative and the absence 
of any serious side-effects.  A simple targets and timetable approach .c.owld  not meet 
these criteria. A general cut in CFCs, for example 50% in 1999, would be somewhat 
arbitrary,  and  could  not  protect  the  patients  using  CFC  products  for  which  no 
alternative had yet been developed.  It is therefore safer to adopt a strategy where the 
phaseout of  CFCs is triggered by the real availability of  alternatives, rather than being 
based on predictions of  when these alternatives might be available. 
7. 7  It is  also  difficult  to  defend  a  strategy  under  which  CFCs  have  to  remain 
available  until  every  single  product  now  using  them  has  been  individually 
reformulated.  This  would  prolong  the  phaseout  indefinitely,  as  certain  products 
currently using CFCs may never be  reformulated and  others may take many years 
before  successful  reformulations  are  launched.  Under the  Protocol's essential  uses 
exemption,  CFCs  must  be  withdrawn  once  there  is  available  "a  technically  and 
economically  feasible  alternative  or  substitute  which  is  acceptable  from  the 
standpoint of  environment and health. "  This does not imply that the alternative must 
be identical either in brand or active substance to  the  CFC product it replaces.  For 
example,  some patients currently using one  brand of beta agonist  might  find  they 
could switch to  an alternative manufactured by another company.  Others  currently 
using an inhaled steroid such as beclomethasone might find they could easily change 
to another active substance with similar properties, whether or not manufactured by 
the  same company.  Some patients currently using a CFC  MDI  could  change to  an 
existing or new multi-dose dry powder inhaler. 
Phase out of  existing CFC MD Is in the EC 
7.8  A strategy based simply on a brand by  brand or active substance by  active 
substance substitution would, without any particular justification,  freeze the current 
production and use patterns of branded medicines.  It would also restrict some of the 
flexibility  between different brands and  between different types of products  which 
will be a necessary part of  a successful transition away from CFC inhalers  Not all the 
current CFC products will be reformulated and some switching between brands and 
between products will be necessary.  Therefore this strategy is  based on phasing out 
CFCs  as  far  as  possible  category  by  category  while  taking  account  of known 
limitations to  substitution within categories of active substance, the  need to  ensure 
that all patients continue to have access to the medicines they require and the different 
circumstances operating in different Member States and. 
7.9  As has already been noted, products for the treatment of asthma and COPD are 
classified into the following 6 categories: 
A  Short acting beta agonist bronchodilators e.g. salbutamol terbutaline, fenoterol 
B  Inhaled Steroids e.g. beclomethasone, budesonide, fluticasone, 
C  Non Steroidal anti-inflammatories e.g. cromoglycate, nedocromil 
27 D  Anticholinergic bronchodilators e.g. ipratropiwn bromide, oxytropiwn bromide 
E  Long acting beta agonists bronchodilators e.g. salmeterol, formoterol 
F  Combination drugs 
Categories A and B together account for approximately [80%] ofCFC MDis used in the 
EC. There are many different brands currently available in these two categories while in 
the  other  categories  there  are  only  one  or  two  brands  on  the  market:  The  active 
substances in each category are phannacologically closely related, are indicated for the 
treatment  of the  same  conditions  and,  with  adequate  consideration  of dosages  and 
action,  most patients would be able to use another product within the category as  an 
alternative. In addition to MD Is, there is also a complete range of DPis for each of the 
Categories A to E.  While they may not currently be the alternative of choice for many 
doctors  and  patients,  dry  powder  inhalers  could  provide  an  effective  and 
environmentally benign alternative for a significant nwnber of patients, if appropriate 
actions are taken at national level to encourage their use.  For these reasons and under 
this  strategy,  CFCs can be phased out for  the manufacture of MDis  within the  EC 
without waiting for each individual MDI currently using CFCs to be reformulated. 
7.10  Pharmaceutical companies who have developed CFC free MDI alternatives will 
need  actively  to  manage  the  transition  through  doctor  and  patient  education 
programmes.  A  company  which  has  introduced  an  alternative  and  has  adequate 
production and distribution capacity for the new product and successful post-marketing 
surveillance should withdraw the CFC product over a maximwn of 12 months following 
the introduction of  the new product onto the market. 
Technically and Economically Feasible Alternatives 
7.11  Under the Montreal Protocol, essential use exemptions are  granted only where 
there arc "no available technically and economically feasible alternatives or substitutes 
acceptable from the standpoint of environment and health." This section of the strategy 
explains  how  it  can  be  determined  when  technically  and  economically  feasible 
alternatives are available, and the essential use exemption withdrawn. 
7.12  Among existing CFC products, there is a nwnber of  active substances identified 
as necessary for patient health which will  have  to  be  available as  CFC-free products 
before  CFCs  can  fmally  be  withdrawn.  Other  CFC  products  are  not  considered 
necessary for patient health and some may never be reformulated.  Salbutamol accounts 
for over 90% of the European MDI short-acting beta agonist market and some 50% of 
the total MDI market.  Beclomethasone accounts for  over 90% of the  European MDI 
steroid market and some 25% of the total MDI market, while in some Member States, 
budesonide is the most important inhaled steroid. For active substances like these, it is 
necessary to ensure that sufficient alternatives are available to meet the requirements of 
patients before CFCs are withdrawn. 
7.13  Conversely, the products  'Epinephrine'  and  'Phenyl Ephrine'  are  no  longer 
considered essential. Therefore, the Commission will not approve any CFCs for their 
manufacture after I January 1999. 
28 Criteria for determining when sufficient alternatives are available 
7.14  The criteria fall into two groups: those for determining when the use of CFCs 
would  no  longer  be  considered  essential  for  individual  products,  and  those  for 
determining when the use of  CFCs would no longer be considered essential for a whole 
category. These two systems will operate in parallel. 
Individual products 
7.15  CFCs for inhalers containing salbutamol will no longer be considered essential 
when two alternative CFC-free MDis containing salbutamol are available in an adequate 
range of  doses from two different producers. 
7.16  CFCs for inhalers containing beclomethasone will no longer be essential when 
two alternative CFC-free MDis containing beclomethasone are available in an adequate 
range of  doses from two different produeers. 
7.17  CFCs for inhalers  containing  any  other active  substance  will  no  longer  be 
considered essential when one alternative CFC-free MDI  containing the same active 
substance is available. 
Categories of  products 
Category A  - Short acting beta agonist bronchodilators 
7.18  CFCs for inhalers in this category will no longer be considered essential once 
two  CFC-free  products  containing  salbutamol  and  one  other  CFC-free  product 
containing an active substance defined as necessary under this strategy are available in 
an adequate range of  doses. 
Category B - Inhaled Steroids 
7.19  CFCs for inhalers in this category will no longer be considered essential once 
two CFC-free products containing beclomethasone and two other CFC-free products 
containing  different  active  substances  defined  as  necessary  under  this  strategy  are 
available in an adequate range of  doses.  -
Categories C, D and E 
7.20  CFCs  for  inhalers  in  each  of these  categories  will  no  longer  be  considered 
essential  once  one  CFC-free  product  containing  an  active  substance(s)  defined  as 
necessary under this strategy for  the category  concerned is  available  in an adequate 
range of  doses. 
Category F - Combination products 
7.21  CFCs for inhalers in this category will no longer be considered essential once 
there are  CFC-free MDI alternatives for  each of its  component active substances or 
when the essential use status has been withdrawn from the relevant category or product. 
A CFC free combination MDI would not be considered an alternative for either of its 
components  when  deciding  whether  there  are  sufficient  technically  and  feasible 
alternatives available. 
29 TABLE A 
CATEGORY A 
SHORT-ACTING BETA AGONIST BRONCJDODILATORS 
PRODUCTS  # ALTERNATIVES  I #PRODUCERS 
Salbutamol•  2 non-CFC Salbutamol products  I 2 different producers 
Terbutaline•  Clenbuterol  CFCs for all category A products will no longer be considered essential 
Fenoterol•  Bitolterol  once there are available 2 alternative S!!b\ltamol products produced by 
Orciprenaline  Procaterol  2 different producers PLUS  1 other product defmed as necessary under 
Reproterol  this strategy 
Carbuterol  Therefore, these products will  be replaced by a minimum of 3 CFC-
Hexoprenaline  free inhalers (two salbutarnol + one other) 
Pirbuterol 
CATEGORYB 
INHALED STEROIDS 
PRODUCTS  # ALTERNATIVES  #PRODUCERS 
Beclomethasone•  2  non-CFC  Beclomethasone  2 different producers 
products  ·---
Dexamethasone  CFCs for all category B products will no longer be considered essential 
Flunisolide  once  there  arc  available  2  alternative  Beclomethasonc  products 
Fluticasone•  produced by 2 different producers PLUS 2 other products containing 
Budesonide•  different active  substances  defmed  as  necessary  under this  strategy. 
Triamcinolone  Therefore these products will be replaced by a minimum of  4 CFC-free 
products ( 2 Beclomethasone + 2 others). 
CATEGORYC 
NON-STEROIDAL ANTI INFLAMMA  TORIES 
Cromoglicic Acid•  CFCs  for  both  category  C  products  will  no  longer  be  considered 
Nedocromil•  essential once  there  is  one  alternative CFC-free product available  to 
replace either of the two current CFC products. Therefore, the 2 CFC 
Note  both -these  products  are  considered  products  will  be  replaced  by  a  minimum  of one CFC-free product, 
necessary in some Member States  except where both products are considered necessary. 
CATEGORYD 
ANTICHOLINERGIC BRONCHIODILATORS 
Ipratropiurn Bromide  CFCs  for  both  category  D  products  will_ no  longer  be  considered 
Oxitropiurn Bromide  essential once  there  is  one alternative CFC-free product available to 
replace either of  the two current CFC products. 
CATEGORYE 
LONG-ACTING BETA AGONIST BRONCHIODILATORS 
Salmeterol•  CFCs  for  both  category  E  products  will  no  longer  be  considered 
Forrnoterol•  essential once there  is  one alternative CFC-free product available to 
replace either of  the current CFC products. Therefore, the 2 category E 
Note:  Both these products are considered  CFC products will be replaced by a minimum of  one CFC-free product, 
necessary in some Member States  except where both products are considered necessary. 
CATEGORYF 
COMBINATION PRODUCTS 
Combination products will be treated on a case-by-case basis. CFCs for 
combination products will no longer be considered essential once CFC-
free products are available for each of the separate components in the 
combination. 
• th1s denotes products deemed necessary under th1s strategy m one or more Member States 
30 7.22  The European Commission will apply the criteria set out in paragraphs 7.15 to 
7.21  and in Table A to determine whether CFCs remain essential for a  given MDI 
product. However, to reflect the different circumstances of  Member States, CFCs m~y 
have to be approved for a particular product in a particular Member State even after 
the criteria for transition have been met. This would ·be the case, for example, where 
the competent authority of that Member State confirms to the Commission that the 
product remains necessary despite the availability of  alternatives. Not~·ltowever, that 
any derogation along these lines would have to be temporary and would not delay the 
transition elsewhere in the Community. It is important to note that the continued use 
of  CFCs is only possible with the agreement of  the Parties to the Montreal Protocol. 
7.23  The following conditions will also need to be met before it is  considered that 
there  are  sufficient  technical  and  feasible  alternatives  available  for  CFCs  to  be 
withdrawn: 
•  Adequate production and distribution capacity of the CFC-free MDis to meet the 
needs of  all patients covered by the product or category concerned: 
•  An adequate range of  doses and strengths to cover distinct patient subgroups such as 
the elderly or young children 
•  Efficacy of  the alternative products and treatments generally comparable to the CFC 
product they are replacing. Some patients may have a personal preference for CFC 
MD  Is, but this is likely to be overcome by education and would not be the basis of  a 
continued exemption under the Montreal Protocol. 
•  Sufficient post marketing surveillance of the reformulated products and no safety 
problems identified 
The Commission will seek advice from the competent authorities of  the Member States 
and other experts to determine when all these conditions have been met and the CFCs 
withdrawn from a particular product or category. 
How CFCs will be phased out once alternatives are available. 
7.24  Manufacturers of  metered dose inhalers for asthma and COPD currently obtain 
their CFCs after agreement to their essential use requests in two stages. In stage 1, the 
European  Cemmission  applies  to  the  Parties  to  the  Montreal  Protocol  for 
authorisation of a  total  quantity of CFCs to  be used to  manufacture  MDis in the 
European Community in a future year. The Parties to the Montreal Protocol review 
the application and approve a certain quantity, usually two years in advance.  At their 
8th Meeting in Costa Rica in 1996, the Parties agreed on a total of 5610 tonnes to be 
used  by  manufacturers  in the  Community  during  1998.  At  their  9th  meeting  in 
Montreal in 1997, the Parties agreed a total of 5000 tonnes for use by manufacturers 
in the Community during  1999.  These CFCs are  intended for  the manufacture of 
MDis both for the European market and also for export. 
7.25  In  stage  2,  each  manufacturer  applies  to  the  European  Commission  for 
authorisation to acquire and use a quantity of CFCs to produce MD  Is. Their requests 
to the Commission are received in the autumn of  each year in respect of  the following 
year.  The  Commission  reviews  the  requests  and,  after  seeking  the  opinion  of a 
31 Management Committee composed of representatives of all  Member States, takes a 
decision on the precise quantities allocated to  each producer for  the following year  . 
. This decision is notified directly to the companies concerned, and is published in the 
Official Journal. The total quantity authorised by the Commission in stage 2 for  use 
by the manufacturers cannot exceed the total quantity approved by the Parties to  the 
Protocol under stage 1 for the year in question. 
7.26  This two stage process means that the Community has a rather flexible means 
to ensure that CFCs can be phased down carefully in line with the availability of  CFC-
free alternatives for each of the categories in Table A.  Using forecasts from the MDI 
manufacturers about the likely submission, approval and registration of alternatives, it 
is possible to predict some years into the future  the likely demand for  CFCs. These 
forecasts can be used as a basis for the Community's nomination to the Parties to  the 
Montreal Protocol two years in advance of need. This is the 'targets and timetables' 
approach to transition advocated by the MDI manufacturers 
7.27  Within these overall totals, the Commission, working in cooperation with the 
Management Committee of Member States and the companies concerned,  can use the 
annual decision on CFC quantities to  "fine tune" the actual  quantities approved for 
each company. For example, should alternatives be  approved earlier than forecast or 
producers have large stockpiles of CFCs, the quantities approved by the Commission 
would be  reduced accordingly.  Conversely,  should alternatives  not be  available  as 
quickly as predicted, there would be some flexibility to distribute the available CFCs 
among  producers  and  among  particular  products  in  order  to  ensure  that  vital 
medicines  remained  available.  Should  the  Community's  transition  be  delayed  for 
some reason, the Commission could even submit a revised bid to the Parties one year 
ahead requesting additional CFCs. However, such a request would only be submitted 
under ex~eptional circumstances. 
7.28  As  regards  the  likely  timetable  for  phasing  out  CFCs  in  line  with  the 
availability of alternatives,  much depends on  how "availability"  is  defined.  A new 
alternative  could  not  be  considered  "available"  on  the  day  of  launch.  Some 
considerable time is  necessary for doctors and  patients to  become aware of the new 
product, to try it out and to  gather information on its performance and acceptability. 
This  information  would  form  part  of the  post-marketing  surveillance  information 
which would be  a vital  part of the  transition.  Only  when adequate  post-marketing 
~urveillance data is available to show that the new alternative is effective, acceptable, 
and without serious side-effects would it be justified to remove the CFC product from 
the market. 
7.29  Gathering adequate post-marketing surveillance data would take  12  months. 
Therefore, once an alternative is launched, the Community could reflect that launch in 
a reduced quantity of CFCs requested from the Parties to the Protocol.  The next year, 
when  the  Commission  comes  to  take  its  decision  on  CFC  quantities,  the  post-
marketing  surveillance  data  would  be  available  and  if the  alternative  has  proved 
successful, no  more  CFCs  need be  authorised  for  the  manufacture of that product. 
Within a maximum of 12 months from the launch of  an alternative, the CFC version it 
replaces would no longer be manufactured for use in the EC. 
32 Stockpiles of  CFCs and CFC containing MD Is 
7.30  Using the  essential  use  decision to  phaseout CFCs for  particular products or 
categories would not of  itself ensure that all the CFC products concerned were taken off 
the market in due time. Companies might continue manufacture using CFCs intended 
for MD  Is in other categories, and manufacturers outside the EC might try to import CFC 
MDis  to  fill  the  gap  in  the  market.  These  problems  will  be  addressed  by  careful 
monitoring of production and stockpiles, import controls and making CFCs available 
only for those products still met the essential uses criteria. 
7.31  Once sufficient technically and economically feasible alternatives exist to enable 
the essential use exemption to be withdrawn for a particular CFC product or category of 
products, no more CFCs will be available for the manufacture of those CFC products. 
Companies  may  still  be  able  to  sell  stockpiled  MDis  which  have  already  been 
manufactured, as there is no obligation to withdraw marketing authorisation. However, 
companies  should  quickly  reduce  their sales  of CFC  products  as  this -would  be  ar 
important means to  ensure the successful take up of their CFC-free alternative.  It is 
possible to envisage a period of 12 months during which the CFC product and its CFC-
free  alternative  are  both available,  particularly  to  assist post-marketing  surveillance. 
After that time, however, the continued presence of  CFC products on the market will be 
unnecessary,  and  might  confuse  doctors  and  patients  involved  in  the  transition. 
Companies should prepare plans to withdraw their CFC products within the suggested 
timeframe and in accordance with their doctor and patient education programmes. 
NewMDis 
7.32  This  strategy  will  not  succeed  if new  MDis  containing  CFCs  are  being 
introduced onto the European market during the transition. To do so would confuse 
patients  and  health  professionals  and  needlessly  prolong  our  reliance  on  CFCs. 
Therefore, as part of  this strategy from 1 January 1998, 
•  competent authorities should not give marketing authorisation to any new CFC-
containing inhalers 
•  the  European  Commission  will  not  approve  the  allocation  of CFCs  for  the 
manufacture of  any new MDI product 
•  Companies should cease developing and promoting CFC-containing MDis. 
33 CHAPTERS  AWARENESS RAISING 
8.1  The transition away from CFC MDis has already started in Europe and should 
largely be completed by the year 2003. The level of awareness of  dry powder inhalers 
(DPis) and CFC-free MDis among health professionals and patients is  still limited, 
however, and this has to change. As more alternatives become available, it is essential 
that an active strategy to inform and involve patients is developed. ThlB will require a 
concerted effort, led and coordinated by National Governments with the support and 
input  of  health  professionals,  health  services,  patient  associations  and  the 
manufacturers of asthma medicines. Adequate funds need to  be identified for raising 
awareness among health professionals and patients if  successful transition is to occur. 
Changeover and education 
8.2  Changeover to  CFC  free  products  is  unlikely  to  occur smoothly  without  a 
national  or regional  strategy  being  in place.  Although  the  strategies  may  differ  in 
detail  between  Member  States,  some  common  features  can  be  recognised.  There 
should be co-operation between the professionals involved on a local or regional basis 
to  discuss  how  the  transition  is  to  be  implemented.  Contacts  with  patient 
representatives should be established at an early stage to ensure that patients receive 
adequate  information,  both  orally  and  in  writing.  This  is  essential  to  build  the 
confidence of  patients in the new products. Further, the changeover of  patients in one 
region or area should be done at roughly the  same time  to  reduce the  problems of 
providing primary and secondary care and the difficulties which would arise from  a 
long period during which both the old and the new products would be available. 
8.3  Choice  of medication  is  invariably  made  by  the  physician  and  not  by  the 
patient. Patients consider this within the competence of the physician and a reason for 
consultation. The patient expects an explanation for the choice of a specific medicine, 
especially where a change from a familiar product is  involved. Surveys have shown 
that  when  a  change  from  CFC  inhalers  to  alternatives  is  recommended  by  the 
physician and adequate information is given, most patients are happy to -change and 
do so successfully. 
8.4  Education is  a  continuous process,  a partnership  between-professionals  and 
patients involving an exchange of information and adequate opportunity for patients 
to express their fears and concerns. Although physicians are the patients' first source 
of information  on  medication,  patients  do  consult  other  professionals  in  asthma 
treatment, including pharmacists and patient associations, when they  have questions 
about the treatment of their disease. It is therefore of the utmost importance that all 
these parties have the same information and give consistent advice to  patients. With 
adequate  preparation  and  reinforcement  of the  key  messages,  most  patients  are 
expected to enjoy a trouble-free transfer from their CFC inhaler to a CFC-free device. 
Asthma Patient Associations 
8.5  Most European countries have  asthma  patient associations,  although  in  the 
majority of cases they  are  rather small.  The  large  associations  in  the  Netherlands, 
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reputation as an important source of  information for patients. The smaller associations 
can  also  provide  vital  information  for  patients.  Some  associations  have  already 
produced written information for patients on the transition. The European Federation 
of Asthma and Allergy Associations (EF  A)  supports the provision of information by 
distributing  fact  sheets  and  other  written  information  to  members  and  associated 
organisations. 
Raising Awareness 
8.6  To raise awareness,  the following actions should be taken: 
(i)  at government level: 
Health  Departments  should  ensure  that  information  is  provided  to  health 
professionals,  including ·unbiased  information  leaflets  for  patients.  Appropriate 
sources of finance  should be  identified to support the awareness raising  campaign. 
National Health Systems and/or Health Insurance Schemes should prepare a plan  to 
manage the period during which new products become available while cheaper CFC 
products remain on the market. 
(ii)  at professional and patient association level: 
8.7  Doctors, nurses  and  pharmacists  need to  be  aware that the transition is  not 
optional, and that, over the next few years, all patients currently using CFC products 
will have to  change to  CFC-free devices.  They should be  prepared to  help patients 
understand the reasons for  the change and assist them during the transition. Patients 
will require reassurance that: 
•  The new inhaler is as safe and as effective as the previous CFC inhaler 
•  The new inhaler devices operate in very similar ways to the CFC inhalers 
•  CFCs are damaging to the global environment and not damaging to the health of 
the individual when inhaled from an MDI. 
•  Although they will experience differences in appearance, dosage, taste and 
· sensation when using the new products, these differences do not imply any 
reduction in effectiveness of  the medicines 
8.8  In cooperation with  Patient Associations, an awareness campaign for patients 
should be started. To prepare patients for the change to alternatives, various methods 
are  needed.  Spoken advice, together with written and  audio-visual  reinforcement is 
likely to be necessary, involving some or all of  the following: 
•  Patient associations:  - Patient Associations have  opportunities for  direct  contact 
with patients through telephone helplines,  support groups, regional branches and 
regular meetings. These associations can help to produce written material in a form 
which  patients  understand.  Similarly,  articles  in  medical  journals  inform 
professionals of  the need and timetable for transition. 
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phaseout of CFCs in MD Is and the new reformulated products. The  US  National 
Heart  Lung and  Blood  Institute  (NHLBI)  and  WHO  have  introduced  a  Global 
Initiative on Asthma (GINA).  This will  increase  international  awareness of this 
subject at symposia throughout Europe, and on the Internet. 
•  Medical  Symposia  - Physicians,  researchers  and  pharmaceutical  development 
experts will present, discuss and evaluate the advances and latest aevelopment of 
alternative treatment. During the next few years, many more symposia are planned. 
In  December  1998,  the  World  Asthma  Meeting  in  Barcelona  will  have  CFC 
transition as a plenary session. The different associations of General Practitioners 
and  Lung  Physicians can provide a  forum  for  discussion  and  evaluation of the 
latest  developments  in  alternative  treatments,  and  the  promotion  of a  wider 
understanding of  the timetable and management of  the transition. 
•  Promotional Material  - Advertising  and  promotional  material  placed in medical 
journals  and  circulated  to  physicians  by  pharmaceutical  companies.  It  will  be 
critical  that  patients  understand  that  the  need  for  the  change  is  based  on 
environmental considerations and not for reasons of  product safety or cost. 
•  Support Groups - which provide information, seminars and programmes aimed at 
both the general community and targeted through schools, sporting groups etc. For 
example, the  UK  National Asthma Campaign has produced a  fact  sheet to  help 
prepare patients for changeover of  their inhalers. 
•  Media Coverage - both national  and  local  media can  play  an  important role  in 
raising awareness among patients and, in particular, encouraging them to  discuss 
their  transition  with  health  professionals.  As  with  all  media  contacts,  care  IS 
requir~d to ensure that the right messages are communicated in a positive way. 
(iii)  at industry level: 
8.9  Manufacturers of MDis  can  help  in  educating  the  medical  profession  by 
advertising  and  placing  educational  material  in  medical  journals,  by -supporting 
medical symposia and by making available reprints of pertinent articles and reports. 
They can also produce information sheets for  patients and  invent strategies to  help 
inform both professionals and the  public of developments and  alternatives.  A good 
example  is  the  brochure  for  professionals  entitled  "Moving  Towards  CFC-free 
Metered  Dose  Inhalers",  produced  by  the  International  Pharmaceutical  Aerosol 
Consortium(IPAC). 
8.10  This educational activity should involve increasing awareness of  DPis as well 
as the reformulated MDI products.  As more alternatives become available it is 
essential that a more active patient strategy is developed to prevent confusion. 
How and When to proceed 
8.11  The awareness raising campaign should start as soon as possible, as many new 
products  are  expected  to  become  available  during  1998.  Strategies  to  manage  the 
transition of  most patients to non-CFC alternatives will need to be ready by the end of 
36 1998.  General  information  on  the  phaseout  of CFCs  and  their  replacement  by 
alternative forms of treatment have to be available when the campaign starts or soon 
afterwards. Specific information and relevant facts on reformulated MDis should be 
provided by the pharmaceutical industry in advance of the launch of new products, 
and during the period of  transition from CFC MDis to the new alternatives. Sources of 
financial  support for  these  activities  have  to  be  identified  as  some partners in  the 
awareness raising campaign might not have  sufficient means  to cov.a- -the  costs of 
their contributions. 
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37 CHAPTER9  EXPORTS OF MDis FROM THE EC 
9.1  Half of the world's production of  MD Is takes place in the EC, and 25% of  the 
Community's MDI  production is  exported.  Approximately  10  million units  go  to 
developing countries each year.  In addition, MDI manufacturing facilities located in 
developing countries and operated by multinational companies often import supplies 
of pharmaceutical quality CFCs from the EC.  It is  important that the•transition to 
CFC-free MDis in the EC does not in disrupt the  supply of important asthma and 
COPD  medicines  to  developing  countries ..  Decision VIII/10  of the  Parties  to  the 
Montreal  Protocol  requests companies to  report on  steps  being taken to  provide a 
continuity  of supply  of asthma and  COPD  treatments  (including  CFC  MDis)  to 
developing  countries.  Decision IX/19  says  that  in preparing a transition  strategy, 
Parties  should take  into  consideration the  availability and price of treatments for 
asthma and COP  D in countries currently importing CFC MD Is". 
Special situation of  developing countries under the Protocol: 
9.2  The  Montreal  Protocol  distinguishes  between  developed  and  developing 
countries in the phaseout of ozone-depleting substances.  Whereas CFCs have been 
phased-out since January 1 1996 in developed countries (January 1 1995 in the EC), 
except  for  essential  uses,  developing countries have a "grace period"  under which 
CFCs may continue to be produced and consumed until 201 0 to meet "basic domestic 
needs". 
9.3  Developing countries currently obtain their MDis from  one or more of three 
possible sources: 
•  Imports from developed countries, particularly the EC; 
•  Production within developing countries by multinational companies; 
•  Production within developing countries of  low-cost generic products by 
independent local companies 
9.4  Demand for MD Is in developing countries is likely to increase with increased 
incidence of asthma and COPD, better access to health care, improved diagnosis and 
effective  treatment  becoming  affordable  for  more  people.  Access  to  medicines  in 
developing countries is constrained by costs, particularly for chronic conditions like 
asthma and COPD. Maintaining access to affordable treatment for asthma and COPD 
is a priority for developing countries, and will inevitably involve the MDI producers 
in the EC. 
Strategies and targets for moving export markets to alternatives: 
9.5  While the  EC  is managing its own transition to  CFC-free MDis, we should 
also consider what to do about MDI exports to developing countries. Steps should be 
taken to ensUre that the benefits of  the development and educational efforts carried out 
in the  EC to  enable the transition to CFC-free MDis are transferred to developing 
countries. As  part of the nomination process to obtain essential use CFCs for exports 
38 of MDis, companies will  be  asked to  report on what measures they  are  taking  to 
facilitate the transition among their customers in developing countries. 
9.6  For  example,  each  MDI  manufacturer  should  strive  to  obtain  regulatory 
approval for their CFC-free MDis in developing countries, and make them available 
there as soon as possible. It makes little sense to start new patients other countries on 
CFC inhalers when the CFC-free version is already available. Companies should also 
make efforts to increase awareness and acceptance of alternative inhalation treatment 
methods,  like DPis and  nebulizers.  In accordance with  Protocol  Decision VIII/1 0, 
companies  should  consider  upgrading  their  MDI  manufacturing  facilities  in 
developing countries to enable them to produce CFC-free MDis. 
Forecast ofCFC requirements to manufacture MDis for export until2010: 
9.7  Currently,  companies  request quantities  of CFCs  for  MDI  manufacture  for 
both their home and export markets together.  Decision VIIV9 sets outs an accounting 
framework for  essential use requests which will separately identify the volumes of 
CFCs used in MDis sold in the Community and those used in MDis for export. Even 
with  this  change,  it  will  remain  difficult  to  make  long-term  forecasts  of CFC 
requirements, particularly for developing countries, where economic growth rates will 
drive  future  demand  for  asthma  treatments.  This  will  be  further  complicated  by 
difficulties in predicting the timing of the transition away from CFC MD Is  in these 
countries. Despite these difficulties, predictions of future CFC requirements in MD Is 
for export will have to be made to ensure that sufficient pharmaceutical grade CFC is 
available to meet demand. 
9.8  P~oduction of CFC-containing MDis for export will have to continue in the 
European Community for some time after our own transition has been accomplished. 
Companies applying for essential use CFCs to manufacture MDis for export need will 
need  to  demonstrate  that  they  are  taking  active  steps,  in  co-operation  with  the 
competent authorities of  the countries to which they export, to promote the transition 
to  CFC-free  inhalers  as  quickly  as  possible,  while  maintaining  the  supplies  of 
necessary medicines to patients. 
Obtaining CFCs to manufacture MDis for export after phase-out in the Community 
9.9  In order to meet the commitment entered into in Decision VIII/10 of ensuring 
adequate and continuing supplies of MDis to developing countries,  MDI  producers 
will  need  access  to  reliable  sources  of pharmaceutical  grade  CFCs  in  sufficient 
quantities  to  meet  the  requirements  for  CFC  MDis  until  these  are  phased out  in 
developing countries. Three possibilities exist: 
•  continued CFC production in the EC as normal 
•  periodic "campaign" production in the EC 
•  import of  CFCs from producers in Developing countries. 
These possibilities are discussed further in Chapter 10, 'CFC Production Issues' 
39 CHAPTER 10  CFC PRODUCTION ISSUES 
. Introduction 
I  O.I  CFCs for  use  in  the  production of MD Is  are  manufactured  in  the  EC  by  4 
producers. These are: 
AlliedSignal  (The Netherlands) 
Ausimont  (Italy) 
Elf-Atochem  (Spain) 
Rhone Poulenc {UK) 
These  producers also  produce  CFCs  for  the  manufacture of MDis in  a  number of 
developed and developing countries. 
I 0.2  These manufacturing facilities produce CFCs to a defined purity specification 
as  laid  down  by  the  individual  MDI  manufacturer.  CFCs  of specified  purity  are 
necessary to meet the requirements of product registration in the countries where the 
CFC  MDis are  sold.  If an  MDI  manufacturer had  to  change  to  a  different  CFC 
producer (even amongst those within the EC) with a different product purity profile, 
this  could mean that the  MDI  manufacturer would  have  to  re-submit  its  MDis for 
registration. As a result, MDI manufacturers tend to purchase their CFC supplies from 
one or two CFC producers only. 
Future Supply of  CFCs for MDI Manufacture within the EC 
10.3  CFC producers within the EC produce mainly CFC  II and CFC 12 for use in 
MDI manufacture within the EC and worldwide. They also produce CFCs to meet the 
basic  domestic  needs  of countries  operating  under paragraph  I  of article  5 of the 
Montreal Protocol. In 1996, EC CFC producers produced 3,062 tonnes of  CFC 11  and 
4,757 tonnes of CFC I2 for MDI manufacture worldwide and 9,430 tonnes of CFC li 
and  14,280  tonnes  of CFC  I2  to  meet  the  basic  domestic  needs  of Developing 
countries. 
10.4  There has been extensive industrial rationalisation of CFC production within 
the EC during the last few years, and the number of producers has reduced by half. 
CFC production has been concentrated upon small manufacturing facilities which are 
more  economically  viable.  These  facilities  are  only  cost-effective  while  their 
production remains above a minimum level. This minimum level is determined by a 
number of parameters and will be different for each producer. The remaining plants 
stay above the minimum level of production through a combination of  production for 
MD Is and for the basic domestic needs of developing countries. The reduction in the 
quantity of  CFCs required by MDI manufacture during the transition period will cause 
CFC producers in the EC to review the operation of their facilities and may lead to 
further  closures.  However,  although further  rationalisation of production capacities 
cannot be excluded, over the next five years it is likely that demand for CFCs for the 
basic domestic needs of  developing countries will enable the continued operation of  at 
least some CFC production facilities within the EC. 
40 10.5  It has been indicated in the April  1997  TEAP Report that once demand for 
CFCs  reduces  to  below the  minimum  cost-effective  level  for  the  producers,  CFC 
production could be maintained by  running  'production campaigns'  and storing the 
CFCs  until  needed.  For the  reason  set out above,  it is  unlikely  that this  will  be 
necessary  for  the  EC  during  the  transition  period.  However,  the  option of a  final 
production campaign should be maintained for the period towards the end of the EC 
phase-out of CFC MD  Is. Such a 'final campaign' would help maintaiu the economic 
viability of CFC producers. The implications for developing countries are discussed 
below. 
10.6  It is important to remember that integrated pollution control licensing of CFC 
plants  requires  forward  planning  and  does  not  allow  for  'ad  hoc'  production  or 
extensions of production periods. A managed transition strategy will help to forecast 
future  CFC  requirements,  including  the  possible  need  for  a  'final  production 
campaign'. 
Production of  CFCs for MDI Manufacture for Export to Developing countries 
10.7  Decision VIII/1 0 (9)  of the  Parties to  the  Montreal  Protocol  requests  MDI 
manufacturing, companies to  take steps to  provide a continuity of supply of asthma 
and chronic obstructive pulmonary disease (COPD) treatments (including CFC MDis) 
to importing countries. In order that these supplies can be maintained, MDI producers 
need access to reliable sources of pharmaceutical-grade CFCs in sufficient quantities 
to meet the needs of importing countries where the transition to  non-CFC products . 
will proceed more slowly. 
10.8  ~1st  this is unlikely to present a problem during the EC transition period for 
the  reasons  already  discussed,  there  is  a concern that once  CFC  MDis have  been 
phased out in the EC, pharmaceutical-grade CFCs could become in short supply for 
the continued manufacture of  MD Is within the EC for export. 
10.9  Given that there is no  immediate prospect of CFC  shortages for MD Is,  it is 
premature to make firm decisions on CFC production for the future  manufacture of 
MD Is for export to developing countries. A number of  possibilities exist, and it is not 
yet  clear  which  would  represent  the  best  way  forward.  One  option  would  be 
'production  campaigns'  whereby  CFC  manufacturing  facilities  would  be  operated 
from  time  to  time  to  produce  a  sufficient  stockpile  of CFCs  to  supply  MDI 
manufacture  for  export.  Considering  this  approach,  the  April  1997  Technical  and 
Economic Assessment Panel (TEAP) Report indicated that a period of 2 years might 
be required to establish an adequate stockpile ofCFCs through 'campaign production', 
should this be require,d. 
10.10  While this idea is prima facie appealing in terms of possible production cost 
savings, its main disadvantage is the difficulty of accurately assessing future demand 
for CFCs. Further, there are no assurances that CFCs which are stockpiled for perhaps 
5 years will not degrade, nor that the MDis ultimately produced with these stockpiled 
CFCs will not deteriorate faster than MDis produced with freshly-produced  CFCs. 
Current experience is that CFCs are stable over 2 years storage. Another potential risk 
41 from the point of view of patient health is  that CFC  producers  will  produce large 
batches of CFCs and will then close down their production facility. This could mean 
that CFC would no longer be available to manufacture  MDis for export to countries 
where they remain essential to patient health. 
10.11  A  second  possible  source  of CFCs  for  MDI  producers  would  be  from 
production facilities located in developing countries. This is not currently thought to 
be a realistic option. Productiop. facilities in developing countries would need to  be 
registered and the CFCs obtained approved by the competent Regulatory Authorities, 
including those in the country of  MDI manufacture.  The CFC production would have 
to  comply  with  stringent  Good  Manufacturing  Practice  (GMP)  and  demonstrate 
reliable and consistent production to a defined purity specification. This could present 
a challenge for CFC producers in developing countries. 
10.12  Given the continued production of CFCs within the  EC  to  supply the basic 
domestic needs of Developing Parties, it is most unlikely that, over the period of the 
EC  transition,  there  will  be  a  shortage  of pharmaceutical  grade  CFCs  for  the 
manufacture of  MD  Is in the EC, whether for use in the Community or for export. 
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THE ESSENTIAL USE PROCESS: OVERVIEW AND TIMETABLE 
11.1  This Chapter describes the process by which an essential use exemption for the 
Metered Dose Inhaler (MDI) is obtained in the European Community and outlines the 
timetable for the completion of  that process. 
THE ESSENTIAL USE PROCESS: OVERVIEW 
11.2  The  Parties  to  the  Montreal  Protocol  established  the  framework  for  the 
essential use process at their Fourth Meeting in  1992 in Copenhagen.  The essential 
use process in the Community is implemented through the provisions of Regulation 
(EC) 3093/94. 
11.3  The essential use process in the European Community involves three distinct 
elements: 
1.  the nomination of essential uses for  future  years,  including a request for 
specific quantities of  CFCs for essential uses in a given year; 
2.  the assessment of those nominations and  a decision by  the Parties to  the 
Montreal Protocol; 
3.  the  review  and  licensing  of essential  use  quantities  by  the  European 
Commission assisted by the Management Committee of  Member States. 
The steps· that must be taken under each of  these elements are as follows: 
11.4  Nomination 
•  IP  AC prepares and submits nomination requests in each Member State 
where MDis are manufactured; 
•  Member  States  review  the  IP AC  submissions,  add  any  approved 
quantities requested by non-IPAC companies and forward nomination 
requests to the European Commission; 
•  The  European  Commission  reviews  the  nominations  received  from 
Member States, combines them and forwards a nomination on behalf 
of the  European  Community  to  the  United  Nations  Environment 
Programme (UNEP). 
Time Required: Approximately 6 Months 
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•  The Technical Options  Committee (ATOC) and  the  Technology and 
Economic Assessment  Panel  (TEAP)  of the  Parties  to  the  Montreal 
Protocol review nominations and determine if  they meet the criteria for 
an  essential  use  established  by  Decision  IV /25  and  whether  the 
quantities  requested  are  justified.  TEAP  reports  its  findings-- and 
recommendations to the Open-Ended Working Group (OEWG) to the 
Montreal Protocol; 
•  The OEWG reviews  TEAP's recommendations  and  forwards  a  draft 
decision  on  essential  uses  for  consideration  by  the  Meeting  of the 
Parties; 
•  The Meeting of the  Parties decides whether to  the nominations meet 
the  essential  use  criteria  and,  if so,  what  quantities  of controlled 
substances are to be authorised. 
Time Required: Approximately 6-9 months 
11.6  Licensing 
•  The  Commission  issues  a  Notice  to  Users  calling  on  MDI 
manufacturers  to  submit  applications  for  essential  use  authorisation 
indicating the quantities of  CFCs they require for the following year; 
•  MDI manufacturers submit applications for essential use authorisation 
to the Commission; 
•  The  Commission,  in consultation  with  the  Article  16  Management 
Committee,  reviews  applications  submitted  by  MDI  manufacturers, 
allocates quantities of CFCs for essential uses, and issues essential use 
licenses. 
Time Required: Approximately 3-6 months 
11.7  In  any  given  year,  each  element  of the  essential  use  process  is  being 
undertaken  concWTently.  For  example,  the  essential  use  process  in  the  European 
Community in 1997 involved the approval and licensing by the Commission for 1998, 
assessment by TEAP and the Parties of the nomination for  1999, and preparation by 
IPAC and other companies ofthe nomination for 2000. 
The diagram below shows the Essential Use Process in the European Community in 
1997 
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The diagram below describes the timetable for the essential use process in 1997: 
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